Method for treating cervical cancer

Abstract

Use of Interleukin-20 for treating cervical cancer or cells infected with human papilloma virus . IL-20 can be administered alone or in conjunction with radiation or chemotherapeutic agents or surgical excision of the involved cells or lesions.

1 - 7 . (canceled) 
     
     
         8 . A method of inhibiting the proliferation of a human Papillomavirus (HPV)-infected cell in an individual infected with HPV comprising administering to said individual a therapeutically effective amount of interleukin-20 (IL-20). 
     
     
         9 . The method according to  claim 8  wherein IL-20 is administered intravenously, peritoneally, intramuscularly or intralesionally. 
     
     
         10 . The method according to  claim 8  wherein the HPV-infected cell is located within a genital wart or lesion. 
     
     
         11 . The method according to  claim 10  wherein IL-20 is injected into the infected lesion or infected genital wart of the individual. 
     
     
         12 . The method according to  claim 11  further comprising electrocauterization, laser, cryotherapy, or surgical excision of at least the genital wart or lesion infected with HPV. 
     
     
         13 . The method according to  claim 8  wherein IL-20 is a first therapeutic agent that is administered in conjunction with a second therapeutic agent. 
     
     
         14 . The method according to  claim 13  wherein the second therapeutic agent is selected from the group consisting of interferon alpha, interferon beta, podophyllotoxin, podophyllin, 5-fluorouracil, trichloroacetic acid and imiquimod. 
     
     
         15 . The method according to  claim 8  wherein IL-20 is administered at a dosage of about 1 μg to about 1000 μg per kilogram body weight per day.